Aptuit collaborates with Italian drugmaker on IPF

USA-based contract research organization Aptuit has entered an agreement under which it will conduct an integrated discovery project aimed at providing innovative drugs to treat idiopathic pulmonary fibrosis (IPF) in collaboration with Italian family-owned drugmaker Chiesi Farmaceutici.

Both parties will contribute scientifically, with Aptuit providing integrated early Discovery capabilities, including medicinal chemistry and pharmacology, as well as drug metabolism and pharmacokinetics, in order to identify promising compounds for further pre-clinical development.

Dr Jonathan Goldman, chief executive of Aptuit, stated: "This project builds upon the existing relationship between Chiesi and Aptuit in the field of respiratory drug discovery. We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease."